CH0012032048

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision lossRoche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…

1 month ago
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD, at the ASHG conference 2025Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD, at the ASHG conference 2025

Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD, at the ASHG conference 2025

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for…

1 month ago
FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancerFDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…

2 months ago
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASHRoche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most…

2 months ago
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertensionRoche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…

3 months ago
Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

July 22, 2025 12:45 ET  | Source: F. Hoffmann-La Roche Ltd Participation certificates (Partizipationsscheine) with a nominal value of CHF…

4 months ago
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s diseaseRoche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

5 months ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

5 months ago